Silexion advances SIL204 regulatory path amid increased Q1 clinical spending

Silexion Therapeutics (NASDAQ:SLXN) reported its financial results for the first quarter ended March 31, 2026, alongside corporate updates highlighting the regulatory progression of its lead RNA interference (RNAi) asset, SIL204.

The clinical-stage biotechnology company, which specializes in developing therapies for KRAS-driven malignancies, finalized key regulatory pathways as it prepares to initiate its Phase 2/3 clinical trial targeting locally advanced pancreatic cancer.

Operationally, Silexion secured a critical regulatory milestone via formal approval from the Israeli Ministry of Health to launch the multi-center clinical evaluation of SIL204.

Moving to widen its clinical footprint into Western Europe, the company subsequently submitted a comprehensive Clinical Trial Application (CTA) to German health authorities through the European Union's integrated Clinical Trials Information System.

Backed by ongoing Good Manufacturing Practice (GMP) clinical manufacturing partnerships, the company expects to begin initial human patient dosing protocols in the second quarter of 2026.

Financially, Silexion’s cost metrics reflected its stepped-up entry into late-stage trial infrastructure.

Research and development (R&D) expenses more than doubled year-over-year to $1.37 million, driven by subcontractor fees, preclinical toxicology verification, and manufacturing scaled-up milestones.

General and administrative (G&A) expenses also increased to $1.38 million due to legal and corporate compliance overhead connected to its public listing infrastructure.

Consequently, Silexion recorded a quarterly net loss of $2.73 million, or $(0.85) per basic and diluted share, compared to a net loss of $1.70 million in the first quarter of 2025.

Silexion concluded the quarter with cash and cash equivalents of $2.4 million, prompting management to flag that its historical liquidity reserves covered only a few months of core operational activities.

To address near-term capital requirements, the firm executed several targeted post-quarter equity transactions, including an ATM (at-the-market) sales program and a $1 million warrant exercise inducement program finalized in mid-May.

According to corporate management, these combined balance sheet interventions effectively pushed Silexion's total stockholders’ equity back above the $2.5 million threshold required for continued listing on the Nasdaq Capital Market.